Charles River Laboratories International Inc
NYSE:CRL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Charles River Laboratories International Inc (CRL) under the Base Case is USD per share.
Compared with the current market price of 353.34 USD, the stock appears .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 5 years, and what happened after valuations like today’s.
Create a free account · No card needed
Fundamental Analysis
What Charles River Laboratories International Does
Charles River Laboratories helps drugmakers and biotech companies test new medicines before they reach patients. It sells laboratory services, research models such as specialty animals, and tools used in early drug discovery and safety testing. Its work sits in the middle of the pharmaceutical development process: customers use Charles River to find drug candidates, test how they behave in the body, and check whether they are likely to be safe enough to move forward.
- Headquarters
- United States of America US
- Employees
- 19 000
- IPO date
- Jun 23, 2000
Charles River Laboratories International has no economic moat
Customers can use other laboratories or their own research teams, while providers compete on price for similar work. Since Charles River does not control a market that excludes new competitors, its size and reputation alone do not prevent rivals from winning business.
Read the full moat analysis
Revenue & Expenses Breakdown
Charles River Laboratories International Inc
Earnings Waterfall
Charles River Laboratories International Inc
What is the Intrinsic Value of one CRL stock?
The intrinsic value for Charles River Laboratories International Inc (CRL) under the Base Case is USD.
Is CRL stock undervalued or overvalued?
Compared with the current market price of 353.34 USD, the stock appears .
